COMMUNIQUÉS West-GlobeNewswire
-
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
25/06/2026 -
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
25/06/2026 -
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
25/06/2026 -
Canadian Red Cross and Walmart Canada launch annual giving campaign
25/06/2026 -
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
25/06/2026 -
Survey Exposes a Crisis of Avoidance in Family Caregiving
25/06/2026 -
Nanox Announces First Quarter 2026 Financial Results and Provides Business Updates
25/06/2026 -
Aeroflow Health Acquires Canopie to Close the Maternal Care Gap for Millions of New Mothers
25/06/2026 -
Arrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEO
25/06/2026 -
New PerfectServe Research: 85% of Healthcare Leaders Want to Switch Their Contact Center Vendors, But Most Feel Trapped
25/06/2026 -
DeepView® System Highlighted at the 2026 British Burn Association Annual Conference
25/06/2026 -
Medera Announces Independent Data Monitoring Committee (DMC) Recommends Continued Advancement of Lead HFpEF Gene Therapy Program
25/06/2026 -
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
25/06/2026 -
Wandercraft Names National Seating & Mobility the Exclusive CRT Distribution Partner for Eve™ Personal Exoskeleton
25/06/2026 -
Glass House Brands Announces Uplist to NYSE
25/06/2026 -
Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel
25/06/2026 -
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
25/06/2026 -
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes
25/06/2026 -
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
25/06/2026
Pages